Supplementary Materials

The PDF file includes:

  • Fig. S1. Hybrid C2H2 zinc finger library screen for pomalidomide-induced degrons.
  • Fig. S2. Hybrid C2H2 zinc finger library screen for avadomide-induced degrons.
  • Fig. S3. Hybrid C2H2 zinc finger library screen for iberdomide-induced degrons.
  • Fig. S4. Validation of individual hybrid zinc finger degrons.
  • Fig. S5. Jurkat models of lenalidomide OFF-switch control of degradable CAR function.
  • Fig. S6. CAR degradation is E1 and neddylation dependent.
  • Fig. S7. Kinetics of CAR degradation and reexpression.
  • Fig. S8. SD-CAR activity against low-antigen tumor cells.
  • Fig. S9. Expression, function, and lenalidomide OFF-switch regulation of super-degron–tagged CARs targeting BCMA.
  • Fig. S10. Therapeutic lenalidomide concentrations inhibit super-degron OFF-switch degradable CARs with CD28 and CD3z signaling domains.
  • Fig. S11. Luciferase-tagged degradable CAR abundance can be monitored by bioluminescence.
  • Fig. S12. Antitumor activity of 4-1BB degradable CAR is not inhibited by pomalidomide treatment in NALM6 model.

[Download PDF]

Other Supplementary Material for this manuscript includes the following: